Secret Key Extraction from Level Crossings over Unauthenticated Wireless Channels

Suhas Mathur,W. Trappe,N. Mandayam,Chunxuan Ye,A. Reznik

DOI: https://doi.org/10.1007/978-1-4419-1385-2_9

Abstract:

What problem does this paper attempt to address?

Safety and efficacy studies of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific responses

Giacomo Frati,Megane Brusson,Gilles Sartre,Bochra Mlayah,Tristan Felix,Anne Chalumeau,Panagiotis Antoniou,Giulia Hardouin,Jean-Paul Concordet,Oriana Romano,Giandomenico Turchiano,Annarita Miccio

DOI: https://doi.org/10.1101/2024.01.14.575586

2024-04-03

Abstract:Reactivation of fetal hemoglobin (HbF) expression through clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated disruption of regulatory elements involved in γ-globin gene repression is a promising gene therapy strategy for the treatment of sickle cell disease (SCD). However, preclinical studies aimed at optimizing the genome editing process and evaluating the safety of the editing strategy are necessary to translate this approach to the clinics. This is particularly relevant in the context of SCD, a disease characterized by inflammation, which can affect hematopoietic stem and progenitor cells (HSPCs), the target cell population in gene therapy approaches for hematopoietic disorders. Here, we describe a genome editing strategy leading to therapeutically relevant reactivation of HbF expression by targeting the binding sites (BSs) for the leukemia/lymphoma related factor (LRF) transcriptional repressor in the and γ-globin promoters. Electroporation of Cas9 ribonucleoprotein and single guide RNA (sgRNA) targeting the promoters in healthy donor (HD) and patient-derived HSPCs resulted in a high frequency of LRF BS disruption and potent HbF synthesis in their erythroid progeny differentiated and after transplantation into immunodeficient mice. LRF BS disruption did not impair SCD and HD HSPC engraftment and differentiation, but was more efficient in SCD than in HD cells. However, SCD HSPCs showed a reduced engraftment and a myeloid bias compared to HD cells. Importantly, in HSPCs, we detected off-target activity and the intra- and inter-chromosomal rearrangements between on- and off-target sites, which were more pronounced in SCD samples (likely because of the higher overall editing efficiency), but did not impact the target gene expression. Off-target activity was observed and , thus indicating that it does not impair engraftment and differentiation of SCD and HD HSPCs. Finally, transcriptomic analyses showed that the genome editing procedure results in the upregulation of genes involved in DNA damage and inflammatory responses in both HD and SCD samples, although gene dysregulation was more evident in SCD HSPCs. Overall, this study provides evidences of feasibility, efficacy and safety for a genome editing strategy based on HbF reactivation and highlights the need of performing safety studies, when possible, in clinically relevant conditions, i.e., in patient-derived HSPCs.

Bioengineering
Using Crisper in the Treatment of Sickle Cell Disease

John Rheney

DOI: https://doi.org/10.47611/jsrhs.v12i1.3889

2023-02-28

Journal of Student Research

Abstract:Individuals with sickle cell disease (SCD) experience many complications and health problems due to their mutated hemoglobin gene; however, these problems could be alleviated by using CRISPR gene editing to alter which hemoglobin variants hematopoietic stem progenitor cells produce. The aim of this review is to determine if it is safe and effective to treat patients with SCD with CRISPR. The findings of “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β Thalassemia” found an increase in fetal hemoglobin expression in patients after transplanting hematopoietic stem progenitor cells with edits to the BCL11A transcription factor. “Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia” also raised fetal hemoglobin by editing hematopoietic stem progenitor cells within their β-globin loci to artificially apply a hereditary persistence of fetal hemoglobin deletional genotype to the cells. Researchers in “CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells” raised wild-type hemoglobin expression in hematopoietic stem progenitor cells affected with SCD by editing the β-globin loci and “fixing” the point mutation that causes SCD. Target deletion efficiency ranged from 18%-80%, and every study used either SpCas9 or SaCas9. Each study found no punitive off-target effects, and they also succeeded in raising hematopoietic stem progenitor cells levels of their targeted hemoglobin. These results point to using CRISPR as both a safe and effective way to treat SCD.
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Tony W. Ho,J. de la Fuente,S. Soni,Amanda M Li,D. Altshuler,A. Kernytsky,Angela Yen,H. Frangoul,M. Cappellini,S. Sheth,Akshay Sharma,F. Locatelli,R. Handgretinger,Brenda K. Eustace,M. Steinberg,A. Kattamis,M. Mapara,M. de Montalembert,D. Wall,S. Corbacioglu,J. Domm,J. Foell,S. Grupp,Yi-Shan Chen,J. Lekstrom-Himes,D. Rondelli

DOI: https://doi.org/10.1056/NEJMoa2031054

IF: 158.5

2020-12-05

New England Journal of Medicine

Abstract:Transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) are severe monogenic diseases with severe and potentially life-threatening manifestations. BCL11A is a transcription factor that represses γ-globin expression and fetal hemoglobin in erythroid cells. We performed electroporation of CD34+ hematopoietic stem and progenitor cells obtained from healthy donors, with CRISPR-Cas9 targeting the BCL11A erythroid-specific enhancer. Approximately 80% of the alleles at this locus were modified, with no evidence of off-target editing. After undergoing myeloablation, two patients - one with TDT and the other with SCD - received autologous CD34+ cells edited with CRISPR-Cas9 targeting the same BCL11A enhancer. More than a year later, both patients had high levels of allelic editing in bone marrow and blood, increases in fetal hemoglobin that were distributed pancellularly, transfusion independence, and (in the patient with SCD) elimination of vaso-occlusive episodes. (Funded by CRISPR Therapeutics and Vertex Pharmaceuticals; ClinicalTrials.gov numbers, NCT03655678 for CLIMB THAL-111 and NCT03745287 for CLIMB SCD-121.).

Biology,Medicine
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease

Varun Katta,Kiera O'Keefe,Yichao Li,Thiyagaraj Mayuranathan,Cicera R Lazzarotto,Rachael K Wood,Rachel M Levine,Alicia Powers,Kalin Mayberry,Garret Manquen,Yu Yao,Jingjing Zhang,Yoonjeong Jang,Nikitha Nimmagadda,Erin A Dempsey,GaHyun Lee,Naoya Uchida,Yong Cheng,Frank Fazio,Tim Lockey,Mike Meagher,Akshay Sharma,John F Tisdale,Sheng Zhou,Jonathan S Yen,Mitchell J Weiss,Shengdar Q Tsai

DOI: https://doi.org/10.1016/j.ymthe.2024.07.022

2024-07-31

Abstract:Sickle cell disease (SCD) is a common, severe genetic blood disorder. Current pharmacotherapies are partially effective and allogeneic hematopoietic stem cell transplantation is associated with immune toxicities. Genome editing of patient hematopoietic stem cells (HSCs) to reactivate fetal hemoglobin (HbF) in erythroid progeny offers an alternative potentially curative approach to treat SCD. Although the FDA released guidelines for evaluating genome editing risks, it remains unclear how best to approach pre-clinical assessment of genome-edited cell products. Here, we describe rigorous pre-clinical development of a therapeutic γ-globin gene promoter editing strategy that supported an investigational new drug application cleared by the FDA. We compared γ-globin promoter and BCL11A enhancer targets, identified a potent HbF-inducing lead candidate, and tested our approach in mobilized CD34+ hematopoietic stem progenitor cells (HSPCs) from SCD patients. We observed efficient editing, HbF induction to predicted therapeutic levels, and reduced sickling. With single-cell analyses, we defined the heterogeneity of HbF induction and HBG1/HBG2 transcription. With CHANGE-seq for sensitive and unbiased off-target discovery followed by targeted sequencing, we did not detect off-target activity in edited HSPCs. Our study provides a blueprint for translating new ex vivo HSC genome editing strategies toward clinical trials for treating SCD and other blood disorders.
Highly efficient therapeutic gene editing of human hematopoietic stem cells

Yuxuan Wu,Jing Zeng,Benjamin P Roscoe,Pengpeng Liu,Qiuming Yao,Cicera R Lazzarotto,Kendell Clement,Mitchel A Cole,Kevin Luk,Cristina Baricordi,Anne H Shen,Chunyan Ren,Erica B Esrick,John P Manis,David M Dorfman,David A Williams,Alessandra Biffi,Carlo Brugnara,Luca Biasco,Christian Brendel,Luca Pinello,Shengdar Q Tsai,Scot A Wolfe,Daniel E Bauer

DOI: https://doi.org/10.1038/s41591-019-0401-y

Abstract:Re-expression of the paralogous γ-globin genes (HBG1/2) could be a universal strategy to ameliorate the severe β-globin disorders sickle cell disease (SCD) and β-thalassemia by induction of fetal hemoglobin (HbF, α2γ2)1. Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adult-stage erythroid cells but are dispensable in non-erythroid cells2-6. CRISPR-Cas9-mediated gene modification has demonstrated variable efficiency, specificity, and persistence in hematopoietic stem cells (HSCs). Here, we demonstrate that Cas9:sgRNA ribonucleoprotein (RNP)-mediated cleavage within a GATA1 binding site at the +58 BCL11A erythroid enhancer results in highly penetrant disruption of this motif, reduction of BCL11A expression, and induction of fetal γ-globin. We optimize conditions for selection-free on-target editing in patient-derived HSCs as a nearly complete reaction lacking detectable genotoxicity or deleterious impact on stem cell function. HSCs preferentially undergo non-homologous compared with microhomology-mediated end joining repair. Erythroid progeny of edited engrafting SCD HSCs express therapeutic levels of HbF and resist sickling, while those from patients with β-thalassemia show restored globin chain balance. Non-homologous end joining repair-based BCL11A enhancer editing approaching complete allelic disruption in HSCs is a practicable therapeutic strategy to produce durable HbF induction.
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 cell therapy to induce fetal hemoglobin for sickle cell disease

Varun Katta,Kiera O’Keefe,Yichao Li,Thiyagaraj Mayurathan,Cicera R. Lazzarotto,Rachael K. Wood,Rachel M. Levine,Alicia Powers,Kalin Mayberry,Garret Manquen,Yu Yao,Jingjing Zhang,Yoonjeong Jang,Nikitha Nimmagadda,Erin A. Dempsey,GaHyun Lee,Naoya Uchida,Yong Cheng,Frank Fazio,Tim Lockey,Mike Meagher,Akshay Sharma,John F. Tisdale,Sheng Zhou,Jonathan S. Yen,Mitchell J. Weiss,Shengdar Q. Tsai

DOI: https://doi.org/10.1101/2024.04.30.591737

2024-05-02

Abstract:Sickle cell disease (SCD) is a common severe blood disorder, caused by one major point mutation in the gene. Current pharmacotherapies are only partially effective and potentially curative allogeneic hematopoietic stem cell transplantation (HSCT) is associated with immune toxicities. Genome editing of autologous patient hematopoietic stem cells (HSCs) to reactivate fetal hemoglobin (HbF) in erythroid progeny offers a potentially curative approach to treat SCD and circumvents some problems associated with allogeneic HSCT. Although the FDA has released guidelines for evaluating genome editing risks, it remains unclear how to best to assess the preclinical safety and efficacy of genome-edited cellular drug products to prepare for a clinical trial. Here we describe rigorous pre-clinical characterization and optimization of a therapeutic γ-globin gene promoter editing strategy that supported an investigational new drug (IND) application cleared by the FDA. We compared targets in the γ-globin promoter and erythroid-specific enhancer, identified a lead candidate that potently induces HbF, and tested our approach in mobilized CD34 HSPCs from normal donors and individuals with SCD. We observed efficient editing, induction of HbF to levels predicted to be therapeutic, and reduction of sickling in red blood cells derived from edited HSPCs. With single-cell western and RNA-seq analyses, we defined the heterogeneity and specificity of HbF induction and transcription. With CHANGE-seq for sensitive and unbiased genome-wide off-target discovery followed by multiplexed targeted sequencing, we did not detect off-target activity in edited HSPCs. Our study provides a blueprint for translating new discoveries on genome editing of HSCs towards clinical trials for treating SCD and other blood disorders.

Genomics
Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation.

R. Peebles,R. Peebles,Mark C. Liu,N. Adkinson,L. M. Lichtenstein,R. Hamilton

DOI: https://doi.org/10.1016/S0091-6749(98)70392-6

IF: 14.29

1998-02-01

Journal of Allergy and Clinical Immunology

Abstract:
Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

Annalisa Lattanzi,Joab Camarena,Premanjali Lahiri,Helen Segal,Waracharee Srifa,Christopher A Vakulskas,Richard L Frock,Josefin Kenrick,Ciaran Lee,Narae Talbott,Jason Skowronski,M Kyle Cromer,Carsten T Charlesworth,Rasmus O Bak,Sruthi Mantri,Gang Bao,David DiGiusto,John Tisdale,J Fraser Wright,Neehar Bhatia,Maria Grazia Roncarolo,Daniel P Dever,Matthew H Porteus

DOI: https://doi.org/10.1126/scitranslmed.abf2444

2021-06-16

Abstract:Sickle cell disease (SCD) is the most common serious monogenic disease with 300,000 births annually worldwide. SCD is an autosomal recessive disease resulting from a single point mutation in codon six of the β-globin gene (HBB). Ex vivo β-globin gene correction in autologous patient-derived hematopoietic stem and progenitor cells (HSPCs) may potentially provide a curative treatment for SCD. We previously developed a CRISPR-Cas9 gene targeting strategy that uses high-fidelity Cas9 precomplexed with chemically modified guide RNAs to induce recombinant adeno-associated virus serotype 6 (rAAV6)-mediated HBB gene correction of the SCD-causing mutation in HSPCs. Here, we demonstrate the preclinical feasibility, efficacy, and toxicology of HBB gene correction in plerixafor-mobilized CD34+ cells from healthy and SCD patient donors (gcHBB-SCD). We achieved up to 60% HBB allelic correction in clinical-scale gcHBB-SCD manufacturing. After transplant into immunodeficient NSG mice, 20% gene correction was achieved with multilineage engraftment. The long-term safety, tumorigenicity, and toxicology study demonstrated no evidence of abnormal hematopoiesis, genotoxicity, or tumorigenicity from the engrafted gcHBB-SCD drug product. Together, these preclinical data support the safety, efficacy, and reproducibility of this gene correction strategy for initiation of a phase 1/2 clinical trial in patients with SCD.
CRISPR/Cas9 Editing Induces High Rates of Unintended Large Gene Modifications in HSPCs from Patients with Sickle Cell Disease

So Hyun Julie Park Park,Mingming Cao,Yankai Zhang,Vivien A. Sheehan,Gang Bao

DOI: https://doi.org/10.1182/blood-2021-150739

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Introduction: Several gene editing strategies have been developed to cure sickle cell disease (SCD), including the use of CRISPR/Cas9 to edit beta-globin (HBB), gamma-globin (HBG), or B-cell lymphoma/leukemia 11A (BCL11A) in hematopoietic stem and progenitor cells (HSPCs) from patients with SCD. Although high gene-editing rates can be achieved and off-target effects reduced, new challenges in applying the gene-editing strategies, including unintended gene modifications, need to be addressed in order to cure SCD with high efficacy and safety. To date, due to limitations in sequencing methods, studies on CRISPR/Cas9 genome editing for treating SCD only identified small insertions/deletions (INDELs); the extent and consequences of unintended large gene modifications are generally unknown. Here we provide accurate quantification and profiling of unintended gene modifications due to Cas9 induced double-stranded breaks (DSBs) in SCD HSPCs, including large deletions, insertions, and complex chromosomal arrangements, and the comparison of different approaches. Methods: R-66S gRNA targets the sickle mutation on the HBB. R-02 gRNA generates a DSB 16 bp away from the sickle mutation site. SD-02 gRNA introduces a 13-bp Hereditary Persistence of Fetal Hemoglobin (HPFH) deletion as a major INDEL in the HBG1/HBG2 promoter to reactivate fetal hemoglobin (HbF). BCL11A gRNA targets the GATA1 site at the BCL11A erythroid enhancer to induce HbF. R-66S, R-02, SD-02, and BCL11A gRNAs were respectively complexed with SpyCas9 and delivered as ribonucleoprotein (RNP) to SCD HSPCs. To accurately quantify CRISPR/Cas9 induced large modifications in gene-edited SCD HSPCs, we used PacBio Single Molecule, Real-Time (SMRT) Sequencing with Unique Molecular Identifiers (UMI). The 5-6 kb region around the Cas9 cut-site was dual-UMI tagged using two PCR cycles. The second and third PCR was performed with minimal cycle numbers to enrich the UMI-tagged template molecules. The SMRTbell library composed of edited and unedited SCD HSPCs samples was sequenced on a PacBio Sequel II 8M flowcell using the circular consensus sequencing (CCS) mode. The PacBio subreads were converted to HiFi reads and subjected to UMI consensus read generation and variant calling. Results: SMRT-seq with UMI revealed high rates and broad spectra of unintended large deletions (> 200 bp) induced by Cas9 cutting at HBB, HBG1, and BCL11A genes in RNP treated samples, with respectively R-66S RNP, 31.7%; R-02 RNP, 17.4%; SD-02 RNP, 13.3%; BCL11A RNP, 40%. The large deletions have a very broad distribution of sizes and locations. In addition, we found large insertions (> 50 bp) and local complex chromosomal rearrangements at the Cas9 cut-sites. Therefore, the current assessment of gene-editing rates using short-read Next Generation Sequencing (NGS) misses a substantial proportion of Cas9-cutting induced large gene modifications, resulting in an inaccurate measure of both allele and genotype frequencies. Discussions: We found that unintended on-target large deletions occur at high rates at HBB, HBG1, and BCL11A in gene-edited SCD HSPCs. These results raise significant safety concerns regarding gene-editing of HSPCs to treat SCD. Our results demonstrate the importance of detecting and quantifying all possible CRISPR/Cas9 gene-editing outcomes to ensure the efficient and safe translation of gene-editing-based strategies to cure SCD and other human diseases. Additional work is required to determine the functional consequences of the unintended gene modifications and the persistence of the unintended large gene modifications at the on-target cut-sites. Disclosures Sheehan: Forma Therapeutics: Research Funding; Beam Therapeutics: Research Funding; Novartis: Research Funding.

hematology
In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model

Chang Li,Aphrodite Georgakopoulou,Kiriaki Paschoudi,Sucheol Gil,Theodore Koob,Lishan Huang,Hongjie Wang,Hans-Peter Kiem,Evangelia Yannaki,André Lieber,Gregory A Newby,Peter J Chen,Kelcee A Everette,Efthimia Vlachaki,Anna K Anderson,David R Liu

DOI: https://doi.org/10.1182/blood.2022018252

IF: 20.3

2023-02-18

Blood

Abstract:Correction of the Sickle Cell mutation and disease phenotypes is achieved by in vivo HSC transduction with vectorized prime editors. Our approach for in vivo HSC prime editing that does not require HSC transplantation and myeloablation should simplify HSC gene therapy. Sickle Cell Disease (SCD) is a monogenic disease caused by a nucleotide mutation in the β-globin gene. Current gene therapy studies are mainly focused on lentivirus vector-mediated gene addition or CRISPR/Cas9-mediated fetal globin reactivation, leaving the root cause unfixed. We developed a vectorized prime editing system that can directly repair the SCD mutation in hematopoietic stem cells (HSCs) in vivo in a SCD mouse model (CD46/Townes mice). Our approach involved a single intravenous injection of a non-integrating, prime editor-expressing virus vector into mobilized CD46/Townes mice and low-dose drug selection in vivo . This procedure resulted in the correction of ~40% of b S alleles in HSCs. On average 43% of HbS was replaced by HbA thereby greatly mitigating the SCD phenotypes. Transplantation in secondary recipients demonstrated that long-term repopulating HSCs were edited. Highly efficient target site editing was achieved with minimal generation of insertions and deletions and no detectable off-target editing. Because of its simplicity and portability, our in vivo prime editing approach has the potential for application in resource-poor countries where SCD is prevalent.

hematology
Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells

Zeng,J.,Nguyen,M. A.,Liu,P.,Ferreira da Silva,L.,Lin,L. Y.,Justus,D. G.,Petri,K.,Clement,K.,Porter,S. N.,Verma,A.,Neri,N. R.,Rosanwo,T.,Ciuculescu,M.-F.,Abriss,D.,Mintzer,E.,Maitland,S. A.,Demirci,S.,Tisdale,J. F.,Williams,D. A.,Zhu,L. J.,Pruett-Miller,S. M.,Pinello,L.,Joung,J. K.,Pattanayak,V.,Manis,J. P.,Armant,M.,Pellin,D.,Brendel,C.,Wolfe,S. A.,Bauer,D. E.

DOI: https://doi.org/10.1101/2023.05.27.542323

2023-05-28

bioRxiv

Abstract:Gene editing the BCL11A erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for β-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its safety and efficacy. Here we compared combined CRISPR-Cas9 endonuclease editing of the BCL11A +58 and +55 enhancers with leading gene modification approaches under clinical investigation. We found that combined targeting of the BCL11A +58 and +55 enhancers with 3xNLS-SpCas9 and two sgRNAs resulted in superior HbF induction, including in engrafting erythroid cells from sickle cell disease (SCD) patient xenografts, attributable to simultaneous disruption of core half E-box/GATA motifs at both enhancers. We corroborated prior observations that double strand breaks (DSBs) could produce unintended on-target outcomes in hematopoietic stem and progenitor cells (HSPCs) such as long deletions and centromere-distal chromosome fragment loss. We show these unintended outcomes are a byproduct of cellular proliferation stimulated by ex vivo culture. Editing HSPCs without cytokine culture bypassed long deletion and micronuclei formation while preserving efficient on-target editing and engraftment function. These results indicate that nuclease editing of quiescent hematopoietic stem cells (HSCs) limits DSB genotoxicity while maintaining therapeutic potency and encourages efforts for in vivo delivery of nucleases to HSCs.
Seeing after blindness

R. Gregory

DOI: https://doi.org/10.1038/nn0903-909

IF: 25

2003-09-01

Nature Neuroscience

Abstract:
Base editing of haematopoietic stem cells rescues sickle cell disease in mice

Gregory A. Newby,Jonathan S. Yen,Kaitly J. Woodard,Thiyagaraj Mayuranathan,Cicera R. Lazzarotto,Yichao Li,Heather Sheppard-Tillman,Shaina N. Porter,Yu Yao,Kalin Mayberry,Kelcee A. Everette,Yoonjeong Jang,Christopher J. Podracky,Elizabeth Thaman,Christophe Lechauve,Akshay Sharma,Jordana M. Henderson,Michelle F. Richter,Kevin T. Zhao,Shannon M. Miller,Tina Wang,Luke W. Koblan,Anton P. McCaffrey,John F. Tisdale,Theodosia A. Kalfa,Shondra M. Pruett-Miller,Shengdar Q. Tsai,Mitchell J. Weiss,David R. Liu

DOI: https://doi.org/10.1038/s41586-021-03609-w

IF: 64.8

2021-06-02

Nature

Abstract:Sickle cell disease (SCD) is caused by a mutation in the β-globin gene HBB<a href="/articles/s41586-021-03609-w#ref-CR1">1</a>. We used a custom adenine base editor (ABE8e-NRCH)<a href="/articles/s41586-021-03609-w#ref-CR2">2</a>,<a href="/articles/s41586-021-03609-w#ref-CR3">3</a> to convert the SCD allele (HBBS) into Makassar β-globin (HBBG), a non-pathogenic variant<a href="/articles/s41586-021-03609-w#ref-CR4">4</a>,<a href="/articles/s41586-021-03609-w#ref-CR5">5</a>. Ex vivo delivery of mRNA encoding the base editor with a targeting guide RNA into haematopoietic stem and progenitor cells (HSPCs) from patients with SCD resulted in 80% conversion of HBBS to HBBG. Sixteen weeks after transplantation of edited human HSPCs into immunodeficient mice, the frequency of HBBG was 68% and hypoxia-induced sickling of bone marrow reticulocytes had decreased fivefold, indicating durable gene editing. To assess the physiological effects of HBBS base editing, we delivered ABE8e-NRCH and guide RNA into HSPCs from a humanized SCD mouse<a href="/articles/s41586-021-03609-w#ref-CR6">6</a> and then transplanted these cells into irradiated mice. After sixteen weeks, Makassar β-globin represented 79% of β-globin protein in blood, and hypoxia-induced sickling was reduced threefold. Mice that received base-edited HSPCs showed near-normal haematological parameters and reduced splenic pathology compared to mice that received unedited cells. Secondary transplantation of edited bone marrow confirmed that the gene editing was durable in long-term haematopoietic stem cells and showed that HBBS-to-HBBG editing of 20% or more is sufficient for phenotypic rescue. Base editing of human HSPCs avoided the p53 activation and larger deletions that have been observed following Cas9 nuclease treatment. These findings point towards a one-time autologous treatment for SCD that eliminates pathogenic HBBS, generates benign HBBG, and minimizes the undesired consequences of double-strand DNA breaks.

multidisciplinary sciences
Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice

Kelcee A Everette,Gregory A Newby,Rachel M Levine,Kalin Mayberry,Yoonjeong Jang,Thiyagaraj Mayuranathan,Nikitha Nimmagadda,Erin Dempsey,Yichao Li,Senthil Velan Bhoopalan,Xiong Liu,Jessie R Davis,Andrew T Nelson,Peter J Chen,Alexander A Sousa,Yong Cheng,John F Tisdale,Mitchell J Weiss,Jonathan S Yen,David R Liu

DOI: https://doi.org/10.1038/s41551-023-01026-0

Abstract:Sickle-cell disease (SCD) is caused by an A·T-to-T·A transversion mutation in the β-globin gene (HBB). Here we show that prime editing can correct the SCD allele (HBBS) to wild type (HBBA) at frequencies of 15%-41% in haematopoietic stem and progenitor cells (HSPCs) from patients with SCD. Seventeen weeks after transplantation into immunodeficient mice, prime-edited SCD HSPCs maintained HBBA levels and displayed engraftment frequencies, haematopoietic differentiation and lineage maturation similar to those of unedited HSPCs from healthy donors. An average of 42% of human erythroblasts and reticulocytes isolated 17 weeks after transplantation of prime-edited HSPCs from four SCD patient donors expressed HBBA, exceeding the levels predicted for therapeutic benefit. HSPC-derived erythrocytes carried less sickle haemoglobin, contained HBBA-derived adult haemoglobin at 28%-43% of normal levels and resisted hypoxia-induced sickling. Minimal off-target editing was detected at over 100 sites nominated experimentally via unbiased genome-wide analysis. Our findings support the feasibility of a one-time prime editing SCD treatment that corrects HBBS to HBBA, does not require any viral or non-viral DNA template and minimizes undesired consequences of DNA double-strand breaks.
Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease

Samuel Lessard,Pauline Rimmelé,Hui Ling,Kevin Moran,Benjamin Vieira,Yi-Dong Lin,Gaurav Manohar Rajani,Vu Hong,Andreas Reik,Richard Boismenu,Ben Hsu,Michael Chen,Bettina M Cockroft,Naoya Uchida,John Tisdale,Asif Alavi,Lakshmanan Krishnamurti,Mehrdad Abedi,Isobelle Galeon,David Reiner,Lin Wang,Anne Ramezi,Pablo Rendo,Mark C Walters,Dana Levasseur,Robert Peters,Timothy Harris,Alexandra Hicks

DOI: https://doi.org/10.1038/s41598-024-74716-7

2024-10-16

Abstract:BIVV003 is a gene-edited autologous cell therapy in clinical development for the potential treatment of sickle cell disease (SCD). Hematopoietic stem cells (HSC) are genetically modified with mRNA encoding zinc finger nucleases (ZFN) that target and disrupt a specific regulatory GATAA motif in the BCL11A erythroid enhancer to reactivate fetal hemoglobin (HbF). We characterized ZFN-edited HSC from healthy donors and donors with SCD. Results of preclinical studies show that ZFN-mediated editing is highly efficient, with enriched biallelic editing and high frequency of on-target indels, producing HSC capable of long-term multilineage engraftment in vivo, and express HbF in erythroid progeny. Interim results from the Phase 1/2 PRECIZN-1 study demonstrated that BIVV003 was well-tolerated in seven participants with SCD, of whom five of the six with more than 3 months of follow-up displayed increased total hemoglobin and HbF, and no severe vaso-occlusive crises. Our data suggest BIVV003 represents a compelling and novel cell therapy for the potential treatment of SCD.
Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin

Cosenza,Zuccato,Zurlo,Gambari,Finotti

DOI: https://doi.org/10.3390/genes13101727

IF: 4.141

2022-09-27

Genes

Abstract:Gene editing (GE) is an efficient strategy for correcting genetic mutations in monogenic hereditary diseases, including β-thalassemia. We have elsewhere reported that CRISPR-Cas9-based gene editing can be employed for the efficient correction of the β039-thalassemia mutation. On the other hand, robust evidence demonstrates that the increased production of fetal hemoglobin (HbF) can be beneficial for patients with β-thalassemia. The aim of our study was to verify whether the de novo production of adult hemoglobin (HbA) using CRISPR-Cas9 gene editing can be combined with HbF induction protocols. The gene editing of the β039-globin mutation was obtained using a CRISPR-Cas9-based experimental strategy; the correction of the gene sequence and the transcription of the corrected gene were analyzed by allele-specific droplet digital PCR and RT-qPCR, respectively; the relative content of HbA and HbF was studied by high-performance liquid chromatography (HPLC) and Western blotting. For HbF induction, the repurposed drug rapamycin was used. The data obtained conclusively demonstrate that the maximal production of HbA and HbF is obtained in GE-corrected, rapamycin-induced erythroid progenitors isolated from β039-thalassemia patients. In conclusion, GE and HbF induction might be used in combination in order to achieve the de novo production of HbA together with an increase in induced HbF.

genetics & heredity
CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease

Meghann McManus,Haydar Frangoul,Martin H Steinberg

DOI: https://doi.org/10.1080/17474086.2024.2429605

2024-12-06

Expert Review of Hematology

Abstract:Introduction Sickle cell disease is ameliorated and perhaps can be 'cured' if enough fetal hemoglobin is present in most erythrocytes. Hydroxyurea, which increases fetal hemoglobin levels, is widely available and effective, especially in children. Nevertheless, only cell-based gene therapy can achieve a 'curative' fetal hemoglobin threshold.

hematology
Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies

Guillermo Ureña-Bailén,Milena Block,Tommaso Grandi,Faidra Aivazidou,Jona Quednau,Dariusz Krenz,Alberto Daniel-Moreno,Andrés Lamsfus-Calle,Thomas Epting,Rupert Handgretinger,Stefan Wild,Markus Mezger

DOI: https://doi.org/10.1089/crispr.2022.0086

Abstract:Cellular therapies hold enormous potential for the cure of severe hematological and oncological disorders. The forefront of innovative gene therapy approaches including therapeutic gene editing and hematopoietic stem cell transplantation needs to be processed by good manufacturing practice to ensure safe application in patients. In the present study, an effective transfection protocol for automated clinical-scale production of genetically modified hematopoietic stem and progenitor cells (HSPCs) using the CliniMACS Prodigy® system including the CliniMACS Electroporator (Miltenyi Biotec) was established. As a proof-of-concept, the enhancer of the BCL11A gene, clustered regularly interspaced short palindromic repeat (CRISPR) target in ongoing clinical trials for β-thalassemia and sickle-cell disease treatment, was disrupted by the CRISPR-Cas9 system simulating a large-scale clinical scenario, yielding 100 million HSPCs with high editing efficiency. In vitro erythroid differentiation and high-performance liquid chromatography analyses corroborated fetal hemoglobin resurgence in edited samples, supporting the feasibility of running the complete process of HSPC gene editing in an automated closed system.
Detection of CRISPR/Cas9-Mediated Fetal Hemoglobin Reactivation in Erythroblasts Derived from Cord Blood-Hematopoietic Stem Cells

Nahal Maroofi,Masoumeh Sadat Mousavi Maleki,Mahsa Tahmasebi,Hamid Reza Khorram Khorshid,Younes Modaberi,Reza Najafipour,Mehdi Banan

DOI: https://doi.org/10.1007/s12033-024-01155-0

2024-04-23

Molecular Biotechnology

Abstract:Reactivation of the fetal hemoglobin (HbF) in adult erythroid cells via genome editing is a strategy for the treatment of β-thalassemia and sickle cell disease. In related reports, the reactivation of HbF is regularly examined in erythroblasts which are generated from the adult CD34 + hematopoietic stem and progenitor cells (HSPCs). However, the procurement of adult HSPCs, either from the bone-marrow (BM) or from mobilized peripheral-blood (mPB), is difficult. Cord-blood (CB) is a readily available source of HSPCs. CB-HSPCs, however, produce high quantities of HbF following differentiation into the erythroid lineage—a potential drawback in such studies. Here, we have edited the BCL11A enhancer (a well-characterized HbF-quantitative trait loci or QTL) via CRISPR/Cas9 in order to determine whether HbF reactivation could be detected in CB-HSPC-derived erythroblasts. In the edited erythroblasts, insertion/deletion (indel) frequencies of 74.0–80.4% and BCL11A RNA reduction levels of 92.6 ± 5.1% ( P < 0.0001) were obtained. In turn, the γ/β-globin transcript ratios were increased from 11.3 ± 1.1-fold to 77.1 ± 2.0-fold, i.e., by 6.8-fold ( P < 0.0001)—and the HbF% levels increased from 34.3% in the control population to 43.5% in the BCL11A edited erythroblasts. Our results suggest that γ-globin/HbF reactivation via genome editing can be detected in CB-HSPCs generated erythroblasts—rendering CB-HSPCs a useful model for similar studies.

biochemistry & molecular biology,biotechnology & applied microbiology
A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.

Chang Li,Anna Kate Anderson,Peter G Ruminski,Michael P Rettig,Darja Karpova,Hans-Peter Kiem,John F. DiPersio,André Lieber

DOI: https://doi.org/10.1182/bloodadvances.2024012757

IF: 7.642

2024-06-10

Blood Advances

Abstract:We have reported direct repair of the sickle cell mutation in vivo in a disease model using vectorized prime editors after hematopoietic stem cell (HSC) mobilization with G-CSF/AMD3100. The use of G-CSF for HSC mobilization would be a hurdle for the clinical translation of the approach. Here, we tested a G-CSF-free mobilization regimen using WU-106, a PEG-conjugated inhibitor of integrin VLA-4 (4β1), plus AMD3100 for in vivo HSC prime editing in sickle cell disease (SCD) mice (CD46/Townes). Mobilization with WU-106+AMD3100 in CD46/Townes mice was rapid and efficient. In contrast to the G-CSF/AMD3100 approach, mobilization of activated granulocytes and elevation of the key pro-inflammatory cytokine IL-6 in serum were minimal. The combination of WU-106+AMD3100 mobilization and intravenous injection of an HDAd-PE5 vector together with in vivo selection resulted in a SCD mutation editing (T>A correction) rate of ~23% in bone marrow and peripheral blood cells of CD46/Townes mice. The treated mice demonstrated phenotypic correction, reflected by normalized blood parameters and spleen size. Editing rates were significantly increased (29%) in secondary recipients indicating preferential mobilization/transduction of long-term repopulating HSCs. Using this approach, we found <1% of undesired indels and no detectable off-target editing at top-scored potential sites. Our study shows that in vivo transduction to treat SCD (including HSC mobilization and HDAd injection) can now be done within 2 hours involving only simple intravenous injections with a good safety profile. The same-day mobilization regimen makes in vivo HSC gene therapy more attractive for the resource-poor settings where SCD does the most damage.

hematology

Secret Key Extraction from Level Crossings over Unauthenticated Wireless Channels

Safety and efficacy studies of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific responses

Using Crisper in the Treatment of Sickle Cell Disease

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease

Highly efficient therapeutic gene editing of human hematopoietic stem cells

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 cell therapy to induce fetal hemoglobin for sickle cell disease

Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation.

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

CRISPR/Cas9 Editing Induces High Rates of Unintended Large Gene Modifications in HSPCs from Patients with Sickle Cell Disease

In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells

Seeing after blindness

Base editing of haematopoietic stem cells rescues sickle cell disease in mice

Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice

Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease

Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin

CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease

Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies

Detection of CRISPR/Cas9-Mediated Fetal Hemoglobin Reactivation in Erythroblasts Derived from Cord Blood-Hematopoietic Stem Cells

A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.